<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>3
<FILENAME>f8k_exhibit.txt
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
                                  Exhibit 99.1


                       IN THE UNITED STATES DISTRICT COURT
                          FOR THE DISTRICT OF MARYLAND
                                SOUTHERN DIVISION

---------------------------------------)
IGEN INTERNATIONAL, INC.,              )
                PLAINTIFF,             )
                                       )
                  v.                   )         CASE NO. PJM 97-3461
                                       )
ROCHE DIAGNOSTICS GmbH,                )
                DEFENDANT.             )
---------------------------------------)

                            FINAL ORDER OF JUDGEMENT

                This action came on for trial before the Court and the Jury,
with the Honorable Peter J. Messitte, United States District Judge, presiding.
The issues having been duly tried, the Jury having duly rendered its verdict,
and the Court having made findings in accordance with the answers to the
specific interrogatories on the Special Verdict Form (attached hereto), and
having concluded that issuance of certain injunctive relief is necessary to
remedy threats of future or recurring breaches,

         IT IS ORDERED AND ADJUDGED as follows:

I.       IGEN'S CLAIMS AGAINST ROCHE DIAGNOSTICS

         A.   MONEY DAMAGES.  Plaintiff IGEN International,  Inc., ("IGEN")
shall recover from Defendant Roche Diagnostics GmbH ("Roche Diagnostics")
$505,406,002 in money damages (subject to an offset of $4,800,000), as set
forth in the special verdict rendered by the jury, as follows:


<PAGE>
        1. The sum of $12,000,000.00 in compensatory damages for Count I of the
        Amended Comp1aint (Breach of Contract-Royalties);

        2. The sum of $5,798,427.00 in compensatory damages for Count II of the
        Amended Complaint (Breach of Contract-Rental Surcharge);

        3. The sum of $807,525.00 in compensatory damages for Count III of the
        Amended Complaint (Breach of Contract-Out-of-Field Sales);

        4. The sum of $10.00 in nominal damages for Count IV of the  Amended
        Complaint  (Breach  of  Contract-Failure  To Ensure  Full Compliance by
        Affiliate Sublicensees);

        5. The sum of $10.00 in nominal damages for Count V of the Amended
        Complaint (Breach of  Contract-Improvement of Assays for "ES" Systems);

        6. The sum of $10.00 in nominal damages for Count X of the Amended
        Complaint (Breach of Contract-Improvements and Patents);

        7. The sum of $10.00 in nominal damages for Count XII of the Amended
        Complaint (Breach of Contract-Improper Settlement of the Serono
        (Delaware) Action);

        8. The sum of  $82,000,000.00 in compensatory  damages for Count XIII
        of the Amended Complaint (Breach of Duty of Good Faith and Fair
        Dealing); and

        9. The sum of $4,800,000.00 in compensatory damages and $400,000,000.00
        in punitive damages for Count XIV of the Amended Complaint (Unfair
        Competition). By virtue of Roche Diagnostics' prior payments to IGEN,
        there shall be an offset in the amount of $4,800,000.00 to the award of
        compensatory damages.


                                       2
<PAGE>

Roche Diagnostics shall pay these sums together with post-judgment interest at
the legal rate and the costs of the action taxable under 28 U.S.C. Section 1920
(to be later calculated).

        B.  DECLARATORY RELIEF.  IGEN is entitled to declaratory relief, and
the Court declares the rights and duties of the parties as follows:

       1.  Roche Diagnostics has materially breached material obligations of
           the License and Technology Development Agreement Between Boehringer
           Mannheim GmbH and IGEN Incorporated (September 23, 1992) (hereafter
           "License Agreement") that are at issue in Counts I (Royalties), III
           (Out-of-Field Sales), X (Improvements), XII (Improper Settlement of
           the Serono (Delaware) Action), and XIII (Breach of Duty of Good
           Faith and Fair Dealing).

       2.  IGEN is entitled to terminate the License Agreement.  The
           Stipulation entered on March 25, 1998, remains in full force and
           effect.

       3.  Roche Diagnostics is obligated to return to IGEN Roche Diagnostics'
           semi-exclusive license to Nucleic Acid Probes (as defined in the
           License Agreement).

        C. PROHIBITORY INJUNCTIVE RELIEF. Defendant Roche Diagnostics and each
of its agents, servants, employees, officers, attorneys, parents, affiliates,
subsidiaries, successors, and assigns, and all persons in privity or in active
concert or participation with Roche Diagnostics are hereby permanently enjoined
and prohibited from directly or indirectly:

  1.  Marketing,  selling,  leasing,  placing, or otherwise distributing the


                                       3
<PAGE>
      Elecsys 1010,  2010,  E170,  or other ECL-based products except where
      they are used solely in hospitals (except where the performance of the
      Assay takes place at the side of the patient), blood banks, or clinical
      reference laboratories.

  2.  Marketing, selling, leasing, placing, or otherwise distributing the
      Elecsys 1010, 2010, E170, or other ECL-based products to physicians'
      office laboratories which, for purposes of this Judgment, are defined as
      laboratories that: (i) are owned by a physician or medical practice and
      (ii) do not perform tests on samples from individuals who are not
      patients of that physician or medical practice. For purposes of this
      Judgment, Laborgemeinschaften, except insofar as they fall within the
      definition of "physicians' office laboratories" specified herein, are
      deemed to be clinical reference laboratories.

  3.  Continuing to sublicense IGEN's ECL technology to "Affiliate
      Sublicensees" (as that term is defined in the License Agreement) without
      taking measures that ensure full compliance with the License Agreement by
      such Affiliate Sublicensees. On a semi-annual basis, Roche Diagnostics
      shall provide to each of its Affiliate Sublicensees, with a
      contemporaneous copy to IGEN, a written description of Roche Diagnostics'
      obligations under the License Agreement and the steps to be taken to
      ensure compliance with those obligations.

        D. MANDATORY INJUNCTIVE RELIEF. Defendant Roche Diagnostics and each of
its agents, servants, employees, officers, attorneys, parents, affiliates,
subsidiaries, successors, and assigns, and all persons in privity or in active
concert or participation with Roche Diagnostics are hereby affirmatively
commanded and directed to take the following actions within the time periods
set forth:

                                       4
<PAGE>

  1.       Roche  Diagnostics  shall,  within 60 days of the entry of this
           Judgment, provide IGEN with a complete list of all past and present
           worldwide  customers of the Elecsys 1010,  Elecsys 2010, E170, or
           other ECL-based  products.  In this list, Roche Diagnostics shall
           specifically identify the segment of the licensed "Field" in which
           each customer falls-that is, a "hospital  laboratory,"  a "clinical
           reference  laboratory,"  or a "blood  bank." If a customer is not a
           "hospital," a "clinical reference laboratory," or a "blood bank,"
           Roche Diagnostics shall identify the type of customer,  including
           whether it is a "physicians' office laboratory."  For purposes of
           this provision, "physicians' office laboratory" is defined as stated
           in Paragraph I.C.2 above.  This customer list, and all information
           contained in the list, shall be designated and treated as "Highly
           Confidential" (except for physician office laboratory customers,
           which shall be designated as "Confidential") pursuant to the
           Confidentiality Stipulation and Protective Order entered in this
           proceeding.

  2.       Roche Diagnostics shall, within 60 days of the end of each calendar
           quarter, until such time as the License Agreement is terminated or
           expires, provide IGEN with updated customer lists meeting the
           criteria specified in Paragraph I.D.1 above.

  3.       With respect to any past or present customer appearing on the list
           specified in Paragraph I.D.1 above that is a pharmaceutical
           company, Roche Diagnostics shall, within 60 days of the entry of
           this Judgment, provide IGEN with a written explanation of the
           nature of the placement, the purpose(s) for which the customer is
           using ECL-based products, and the reason(s) Roche Diagnostics
           believes such customer is a "hospital," "blood bank," or "clinical
           reference 1aboratory."

                                       5
<PAGE>
           With respect to any other reclassified placements appearing on the
           list specified on Paragraph I.D.1 or any new placements on future
           lists, if IGEN believes the placements may fall outside the licensed
           Field (as set forth in the License Agreement), IGEN may, within 30
           days of the receipt of such list initiate the dispute resolution
           procedures set forth in Section 10.1 of the License Agreement to
           determine the proper classification.

  4.       With respect to future placements of the Elecsys 1010, Elecsys 2010,
           E170, or other ECL-based products, Roche Diagnostics shall not
           market, sell, lease, place, or otherwise distribute such products to
           any new customers that are pharmaceutical companies unless Roche
           Diagnostics: (i) provides IGEN with advance notice of the intended
           customer along with a written explanation of the nature of the
           placement, the purpose(s) for which the customer would use ECL-based
           products, and the reason(s) Roche Diagnostics believes such customer
           is a "hospital," "blood bank," or "clinical reference laboratory";
           and (ii) provides IGEN with a period 21 days after receipt of such
           written notice to object in writing to the intended placement.  If
           Roche Diagnostics proceeds with the intended placement over IGEN's
           written objection, IGEN may, in its discretion, initiate the dispute
           resolution procedures set forth in Section 10.1 of the License
           Agreement.

  5.       Roche Diagnostics shall report royalties to IGEN on a quarterly
           basis within the time frame specified in the License Agreement at a
           rate of 9% of Net Sales (as defined in the License Agreement), and
           in any event at an effective rate of not less than 8.325% of all
           amounts invoiced (without any reduction, set-off, or reallocation)
           by Roche Diagnostics and its Affiliate Sublicensees


                                       6
<PAGE>
           for ECL-based instruments, assays, services, and other products and
           accessories that can be used only with ECL-based systems.

  6.       Roche Diagnostics shall deliver to IGEN copies of all existing
           patent applications on "Improvements" (as that term is defined in
           the License Agreement) within 30 days of the entry of this
           Judgment.

  7.       Roche Diagnostics shall deliver to IGEN, within the time specified
           in the License Agreement, copies of all future patent applications
           on "Improvements" created between the entry of this Judgment and
           such time as the License Agreement is terminated or expires.

  8.       In accordance with the Jury's verdict regarding Roche Diagnostics'
           obligation to provide Improvements to IGEN, within 30 days of the
           entry of this Judgment, or 30 days of decision on the applicable
           post-judgment motion(s) (whichever is later), Roche Diagnostics
           shall make available and grant to IGEN for use in products based
           on the ECL technology in fields other than the "Field" (as that
           term is defined in the Agreement) an irrevocable, perpetual,
           fully-paid, non-exclusive license (with the right to sublicense)
           to copy, make, have made, use and/or sell:

               a.       The entire Elecsys 1010 instrument.
               b.       The entire Elecsys 2010 instrument.
               c.       All aspects of the ECL assays that Roche Diagnostics
                        developed under the License Agreement.
               d.       All aspects of the instruments and assays that arose
                        out of the Molecsys program (i.e., the development
                        program for ECL-based DNA probes).
               e.       The polymerase chain reaction ("PCR") technology that
                        was used in connection with the Molecsys program.

                                       7
<PAGE>
               f.       The Roche Diagnostics method for coating magnetic beads.
               g.       The ECL module of the E-170 instrument.

  9.       In furtherance of its obligations in Paragraph I.D.8 above, Roche
           Diagnostics shall provide to IGEN: (i) documents, protocols,
           formulas, specifications, systems specifications, design drawings,
           processes, data, controls, materials, regulatory filings, know-how,
           show-how in the possession, custody, or control of Roche Diagnostics
           and/or any of its subcontractors (e.g., Hitachi), and (ii) all other
           information and materials required or necessary to enable IGEN to
           design, develop, replicate, manufacture, validate, obtain regulatory
           approval for, and commercialize such Improvements. Roche Diagnostics
           shall respond in a timely manner to all reasonable requests by IGEN
           for information and make personnel of Roche Diagnostics and/or any
           of its subcontractors (e.g.,  Hitachi) available to IGEN for on-site
           and/or other consultation as needed to ensure the full transfer of
           all such Improvements. All costs associated with such transfer shall
           be borne by Roche Diagnostics.  Nothing in this Judgment shall be
           construed as a guarantee by Roche Diagnostics of the commercial
           success of any products developed or marketed by IGEN.

  10.      To the extent any of the documents, protocols, systems,
           specifications, processes, data, controls, materials, regulatory
           filings, know-how, and show-how specified in Paragraph I.D.9 above
           are held by or supplied to Roche Diagnostics by a third party,
           Roche Diagnostics shall, within 30 days of the entry of Judgment,
           or 30 days after decision on the applicable post-judgment motion(s)
           (whichever is later), identify such third party or parties and the
           item(s) that such third party (or parties) holds or supplies.

                                       8
<PAGE>
  11.      Roche Diagnostics shall provide to IGEN, in accordance with the
           procedures set forth in Paragraph I.D.9 above, all Improvements
           (as that term is defined in Section 1.6 of the License Agreement)
           created, conceived, or reduced to practice between the entry of
           this Judgment and such time as the License Agreement is terminated
           or expires. Any and all such future "Improvements" shall be
           delivered to IGEN on a quarterly basis.

       E.    INSTRUCTIONS REGARDING CERTAIN PRELIMINARY ORDERS

    1.    The Order and Preliminary Injunction entered on October 19, 1998, is
          superseded by this Judgment.

    2.    The bond in the amount of $750,000.00 that IGEN posted pursuant to
          Paragraph 9 of the Order and Preliminary Injunction entered on
          October 19, 1998, is hereby released.

    3.    The amount held in escrow by Roche Diagnostics pursuant to the Order
          and Preliminary Injunction entered on October 19, 1998, is
          hereby released to Roche Diagnostics.

    4.    The Consent Order concerning the transfer of certain Elecsys customers
          entered on May 4, 2000, is superseded by this Judgment.

    5.    The Supply, Services and Support Agreement, dated as of May 1, 2000,
          as may be amended by the parties, shall remain in full force and
          effect.

    6.    With respect to customers transferred by Roche Diagnostics to
          IGEN pursuant to the Consent Order:

                                       9
<PAGE>
        a. Roche Diagnostics shall not terminate contracts with such customers
           without good cause.  Roche Diagnostics shall not be required by this
           Order to renew existing contracts with transferred customers, unless
           otherwise required by an existing customer contract.  To the extent
           that some or all of the contracts with transferred customers are
           scheduled to expire prior to the final disposition of this action,
           the parties may agree to extend those contracts, or in the event of
           a disagreement, may seek the Court's resolution of the dispute.
           Neither Roche Diagnostics nor IGEN shall amend, modify, or extend
           existing agreements with transferred customers without the prior
           written consent of the other party, which will not be unreasonably
           withheld, except that (a) if an existing transferred customer
           requests an expansion of its monthly assay requirements (in quantity,
           in nature; or both), IGEN shall be permitted to provide the
           additional assays without the written consent of Roche Diagnostics,
           (b) IGEN may increase the prices of ECL-based products sold to
           transferred customers, if the customers agree to such price
           increases, and (c) IGEN may discount a particular customer invoice
           if it so desires, but IGEN's payments to Roche Diagnostics for
           service pursuant to the terms of the Supply Agreement shall be based
           on the non-discounted customer invoice price.

        b. IGEN is not required by this Judgment to assume the financial risks
           associated with the termination of contracts with such customers.

        c. Roche Diagnostics shall provide to IGEN, within 30 days of the entry
           of this Judgment, a written description of all third-party financing

                                       10
<PAGE>
           obligations with respect to such customers, including an
           identification of each customer for which a third-party financing
           obligation exists and, for each such customer, the duration of the
           obligation, the amount of and due date for each periodic payment,
           and that name and address of the entity to which payments must be
           made.

       7. The amount held in escrow by IGEN pursuant to the Consent Order is
          hereby released to IGEN, and IGEN is hereby relieved of the escrow
          obligations set forth in Paragraph 1(a) of the Consent Order.

        F. REMAINING COUNTS. Plaintiff IGEN takes nothing on the following
Counts of the Amended Complaint: VI (Breach of Contract-Cobas Systems), VII
(Breach of Contract-Failure to Place DNA Probe Assays on ECL-based Systems),
and VIII (Breach of Contract-Failure to Commercialize Competitive Product Line
(Immunoassays)), and Counts VI, VII and VIII are dismissed on the merits.

II.      ROCHE DIAGNOSTICS' COUNTERCLAIMS AGAINST IGEN

         A. MONEY DAMAGES.  Roche Diagnostics shall recover from IGEN
$500,000.00 in compensatory damages for Counterclaim II (Breach of Duty of
Good Faith and Fair Dealing) as set forth on the Special Verdict Form, together
with post-judgment interest at the legal rate.

         B. REMAINING  COUNTERCLAIMS.  Roche Diagnostics takes nothing on
Counterclaim I (Breach of Contract-Extension of Eisai's Rights in Japan) or
Counterclaim III (Breach of Contract-Improvements), and Counterclaims I and III
are dismissed on the merits.


                                       11
<PAGE>

III. CONTINUING JURISDICTION

         The Court shall retain jurisdiction over the action for the purpose of
enforcing the terms of this Judgment.


         DATED THIS 15 DAY OF FEBRUARY, 2002.


                                                      /s/ PETER J. MESSITTE
                                                      ---------------------
                                                       PETER J. MESSITTE
                                                 UNITED STATES DISTRICT JUDGE

                                       12


</TEXT>
</DOCUMENT>